ORASURE TECHNOLOGIES INC OSUR
OTI transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are.
Our products and services reside under one reporting hierarchy, with commercial and innovation teams, which are part of a single business unit covering multiple product lines. Our business is principally comprised of the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions.
In November 2025, the Company acquired BioMedomics, Inc. ("BioMedomics"). BioMedomics' SickleSCAN® test is the world's first rapid point-of-care test for sickle cell disease. The SickleSCAN® test is currently sold in markets outside the U.S.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $115.0M | $185.8M | $405.5M | $387.5M | $233.7M | $171.7M | $154.6M | $181.7M | $167.1M | $128.2M |
| Cost of revenue | $66.8M | $106.4M | $233.8M | $239.0M | $116.1M | $69.9M | $60.0M | $68.1M | $68.1M | $40.2M |
| Gross profit | $48.2M | $79.4M | $171.7M | $148.4M | $117.6M | $101.9M | $94.6M | $113.6M | $99.0M | $88.0M |
| R&D | $42.5M | $26.0M | $33.7M | $36.2M | $34.2M | $31.0M | $19.6M | $16.2M | $13.4M | $9.8M |
| SG&A | $47.7M | $46.2M | $58.2M | $68.2M | $50.3M | $42.7M | $35.3M | $38.3M | $29.3M | $28.4M |
| Total operating expenses | $120.2M | $107.6M | $139.0M | $170.6M | $127.8M | $107.0M | $76.0M | $85.2M | $58.7M | $67.8M |
| Operating income | -$72.0M | -$28.2M | $32.7M | -$22.2M | -$10.2M | -$5.2M | $18.6M | $28.4M | $40.2M | $20.3M |
| Pre-tax income | -$64.6M | -$16.0M | $56.3M | -$15.7M | -$9.3M | -$3.5M | $21.3M | $31.7M | $41.0M | $20.3M |
| Income tax | $1.8M | $1.8M | $2.6M | $1.5M | $13.7M | $11.4M | $4.7M | $11.3M | $10.1M | $603.0K |
| Net income | -$68.7M | -$19.5M | $53.7M | -$17.1M | -$23.0M | -$14.9M | $16.7M | $20.4M | $30.9M | $19.7M |
| EPS, basic | -0.94 | -0.26 | 0.73 | -0.24 | -0.32 | 0.22 | 0.27 | 0.33 | 0.52 | 0.35 |
| EPS, diluted | -0.94 | -0.26 | 0.72 | -0.24 | -0.32 | 0.22 | 0.27 | 0.33 | 0.51 | 0.35 |
| Shares, diluted (wtd. avg.) | $73.5M | $74.4M | $74.4M | $72.5M | $72.0M | $67.5M | $62.2M | $62.5M | $61.0M | $56.5M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $199.3M | $267.8M | $290.4M | $84.0M | $116.8M | $160.8M | $75.7M | $88.4M | $71.0M | $108.0M |
| Short-term investments | — | — | $0 | $26.9M | $36.3M | $48.6M | $80.6M | $68.1M | $83.0M | $11.2M |
| Receivables | $22.2M | $23.8M | $40.2M | $70.8M | $45.3M | $38.8M | $36.9M | $34.8M | $42.5M | $19.8M |
| Inventory | $31.1M | $34.2M | $47.6M | $95.7M | $53.1M | $31.9M | $23.2M | $22.9M | $19.3M | $11.8M |
| Total current assets | $261.9M | $333.2M | $386.5M | $325.2M | $299.3M | $288.9M | $224.6M | $219.3M | $221.9M | $156.4M |
| Property, plant and equipment | $39.2M | $45.1M | $45.4M | $59.4M | $73.4M | $51.9M | $30.3M | $24.3M | $21.4M | $20.0M |
| Goodwill | $43.4M | $40.3M | $35.7M | $35.1M | $40.3M | $40.4M | $36.2M | $18.5M | $20.1M | $18.8M |
| Other intangibles | $19.0M | $17.4M | $1.2M | $11.7M | $14.3M | $17.9M | $14.7M | $5.1M | $8.2M | $10.3M |
| Total assets | $403.2M | $479.7M | $482.8M | $444.2M | $461.0M | $454.5M | $349.3M | $315.6M | $296.2M | $207.9M |
| Accounts payable | $6.5M | $8.2M | $13.2M | $38.0M | $28.0M | $17.4M | $9.6M | $10.6M | $10.2M | $4.6M |
| Total current liabilities | $39.8M | $33.5M | $39.5M | $69.1M | $68.1M | $46.5M | $32.7M | $28.0M | $32.2M | $17.3M |
| Total liabilities | $62.3M | $69.3M | $52.2M | $79.8M | $80.5M | $55.9M | $42.1M | $32.2M | — | — |
| Retained earnings | -$172.2M | -$103.4M | -$83.9M | -$137.6M | -$120.5M | -$97.5M | -$82.5M | -$99.2M | -$119.5M | -$150.5M |
| Total equity | $340.8M | $410.3M | $430.7M | $364.4M | $380.5M | $398.6M | $307.1M | $283.4M | $258.1M | $185.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$49.0M | $27.4M | $141.6M | -$47.2M | -$35.4M | $5.8M | $9.8M | $39.1M | $28.2M | $24.6M |
| Depreciation and amortisation | $10.2M | $10.9M | $20.9M | $15.3M | $11.7M | $9.4M | $7.3M | $6.5M | $6.1M | $5.7M |
| Stock-based compensation | $10.1M | $11.9M | $10.7M | $11.6M | $7.8M | $7.1M | $4.1M | $15.2M | $7.0M | $6.1M |
| Capital expenditure | $4.2M | $3.8M | $5.8M | $6.8M | $21.9M | $26.7M | $9.3M | $6.3M | $4.3M | $4.4M |
| Investing cash flow | -$6.8M | -$39.0M | $66.2M | $21.1M | -$5.5M | -$14.0M | -$19.8M | -$17.4M | -$96.4M | -$8.1M |
| Financing cash flow | -$16.9M | -$4.2M | -$3.0M | -$3.8M | -$2.8M | $92.5M | -$4.7M | -$1.9M | $30.4M | -$1.2M |
| Buybacks | $15.0M | $0 | $0 | $2.3M | $2.1M | $2.1M | $3.7M | $3.6M | $1.2M | $3.4M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001116463-26-000032.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |